DriveWealth Names Naureen Hassan Chief Executive Officer
20.8.2025 16:00:00 CEST | Business Wire | Press Release
DriveWealth, a leading financial technology platform providing Brokerage-as-a-Service, has announced the appointment of Naureen Hassan as Global Chief Executive Officer (CEO). Hassan succeeds Michael Blaugrund, who is stepping down as CEO to accept a newly created position at ICE (Intercontinental Exchange).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250820719951/en/
DriveWealth welcomes Naureen Hassan as its new CEO.
Hassan joins DriveWealth with decades of deep expertise in digital and product innovation, operational excellence and regulatory management across global banking and wealth management. She will guide the company’s operations, lead its continued growth and expansion across markets, and help fulfill DriveWealth’s mission of democratizing investing around the world.
“Michael has overseen a period of significant growth, expansion into new markets and profitability over the last two years as CEO and we thank him for everything that he has accomplished,” said Robert Cortright, DriveWealth Founder and Executive Chairman. “Naureen has a proven track record as an industry innovator and disruptor and is the perfect person to lead DriveWealth through our continued evolution and next phase of growth. She joins us during a period of accelerating growth, and we look forward to all that is to come under her visionary leadership.”
Prior to DriveWealth, Hassan served as President of UBS Americas, where she led a $14B revenue division with more than 25,000 employees, while also spearheading UBS’s integration of Credit Suisse in the Americas—the first-ever acquisition between two globally systemically important financial institutions. She also worked at the Federal Reserve Bank of New York, where she drove innovations across payment operations, technology, human resources, risk management, and finance.
Before joining the Fed, Hassan served as Chief Digital Officer of Morgan Stanley’s Wealth Management business and drove strategy and platform innovation for Charles Schwab’s Investor Services division. She began her career at McKinsey & Company.
“DriveWealth is truly changing how and where people invest and providing unique value and capabilities to partners across the globe,” Hassan said. “I am honored to step into this role, to continue building on the great work Robert and Michael have done, and to help guide the company’s continued growth and success. DriveWealth has grown by opening doors to new opportunities for investors in new markets and we will continue to work toward realizing the company’s potential as the market’s most trusted embedded investing technology partner.”
A leading provider of Brokerage-as-a-Service and other critical investment infrastructure, DriveWealth operates in markets across five continents, including the U.S., the EU/UK, South Korea, Australia and New Zealand, and Brazil. The company supports an average of over 2 million trades per day for its B2B partners around the world, facilitating 24-hour trading, fractional share execution and multi-asset class support for millions of individual global investors.
DriveWealth was recently named to CNBC’s “World’s Top Fintech Companies 2025” list and recognized on the 2025 Inc. 5000 list of America’s fastest-growing private companies for the second year in a row.
About DriveWealth:
DriveWealth is a global B2B financial technology platform. Our core business is providing Brokerage-as-a-Service, powering the investing and trading experiences for digital wallets, broker dealers, asset managers, and consumer brands. DriveWealth’s APIs provide our partners with a modern, extensible and flexible toolkit to develop everything from traditional investment workflows to more innovative techniques like rounding up purchases into fractional share ownership. For more information, visit www.drivewealth.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250820719951/en/
Contacts
Media Contact:
Ryan Hall
Caliber Corporate Advisers
drivewealth@calibercorporate.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom